FindTrial
Sign In

Comparison of oliceridine and sufentanil intravenous patient-controlled analgesia for postoperative nausea and vomiting after thoracoscopy: a prospective, double-blind, randomized controlled trial

Comparison of oliceridine and sufentanil intravenous patient-controlled analgesia on postoperative nausea and vomiting after thoracoscopy: a prospective, double-blind, randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094068
Enrollment
Unknown
Registered
2024-12-17
Start date
2024-12-31
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Oliceridine group:Oliceridine group: the analgesic pump formula is oliceridine 0.5mg/kg+tropisetron 6mg, diluted with normal saline to 100ml, with parameter settings of 2ml/h, PCA dose of 0.5ml, and l
Sulfentanil group:Sulfentanil group:the analgesic pump formula is sulfentanil 2µg/kg +tropisetron 6mg,diluted with normal saline to 100ml, with parameter settings of 2ml/h, PCA dose of 0.5ml, and lock

Sponsors

Department of Anesthesiology, Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65 years old; 2. ASAI.-III. 3. Elective thoracoscopic surgery; 4.BMI 18-30kg/m2

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to any of the drugs used in this test and contraindications; 2. Serious underlying diseases (such as cardiovascular and cerebrovascular diseases, respiratory diseases, or abnormal liver and kidney function); 3. History of angina pectoris or myocardial infarction within the past 6 months; 4. Uncontrolled or untreated hypertension (resting systolic/diastolic blood pressure >180/100 mmHg); 5. Long-term use of sedative-hypnotic analgesic drugs; 6. Degree III atrioventricular block; 7. Inability to communicate normally: hearing impairment, language comprehension impairment, mental illness, etc.;

Design outcomes

Primary

MeasureTime frame
The incidence of nausea and vomiting;—

Secondary

MeasureTime frame
Nausea, retching, and vomiting ;VAS of pain scores(at rest/ during coughing) ;Postoperative consumption of sufentanil and oliceridine;First press PCA time; Effective pressing times of PCA within 24 and 48 hours;Use of rescue antiemetics (metoclopramide), use of rescue analgesics (bucinazine hydrochloride);Bruggrmann comfort scale;Ramsay Sedation Scale;Quality of Requirements-15;Athens Insomnia Scale score;Postoperative chest drain removal time;Post-operative length of stay;—

Countries

China

Contacts

Public ContactLInlin Zhao

Department of Anesthesiology, Affiliated Hospital of Xuzhou Medical University

lin1675@163.com+86 181 6877 7313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026